Anoro Ellipta - Instructions For Use, Indications, Doses, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Anoro Ellipta

Instructions for use:

1. 1. Release form and composition
2. 2. Indications for use
3. 3. Contraindications
4. 4. Method of application and dosage
5. 5. Side effects
6. 6. Special instructions
7. 7. Drug interactions
8. 8. Analogs
9. 9. Terms and conditions of storage
10. 10. Terms of dispensing from pharmacies

Prices in online pharmacies:

from 2043 rub.

Buy

Anoro Ellipta is a two-component bronchodilating agent for daily use.

Release form and composition

The dosage form of Anoro Ellipt is a dosed powder for inhalation: white (in plastic inhalers for 30 doses, 1 inhaler complete with two aluminum strips in containers, 1 aluminum foil container in a cardboard box).

1 component

Composition of 1 dose:

• active substance: vilanterol (delivered dose) - 0.022 mg (micronized vilanterol triphenatate - 0.04 mg);
• auxiliary components: magnesium stearate - 125 mg, lactose monohydrate - up to 12.5 mg.

2 component

Composition of 1 dose:

• active substance: umeclidinium (delivered dose) - 0.055 or 0.113 mg (umeclidinium bromide - 0.0742 or 0.1483 mg);
• auxiliary components (regardless of the amount of active substance): magnesium stearate - 75 mg, lactose monohydrate - up to 12.5 mg.

Indications for use

Anoro Ellipta is prescribed as a supportive bronchodilator therapy aimed at relieving symptoms of chronic obstructive pulmonary disease (COPD).

Contraindications

Absolute:

• allergic reactions to milk protein in severe course;
• age up to 18 years;
• hypersensitivity to the components of the drug.

Relative (Anoro Ellipta is prescribed with caution for the following diseases / conditions):

• severe forms of cardiovascular disease (the likelihood of developing arrhythmias);
• angle-closure glaucoma;
• retention of urine.

Pregnant women need to assess the benefit-risk ratio before prescribing therapy (there is no safety profile for this category of patients). During lactation, if it is necessary to use Anoro Ellipt, breastfeeding should be canceled (there is a possibility of the drug entering the child's body with milk).

Method of administration and dosage

Anoro Ellipta is intended solely for inhalation use.

Frequency rate of application - once a day, daily, preferably at the same time.

The recommended single / daily dose is 1 inhalation 0.022 mg + 0.055 mg. In some patients, a dose of 0.022 mg + 0.113 mg has an additional benefit in terms of effects on lung function and the frequency of use of emergency medications. This dose is the maximum.

Do not open the lid of the inhaler in cases where inhalation is not planned (dose loss occurs). You do not need to shake the bottle.

A counter is installed on the vial, if there are less than 10 doses left in the vial, half of the counter turns red.

To carry out the procedure, you need to exhale as much as possible, after which you should place the mouthpiece between your lips, clasp it tightly with your lips, without closing the ventilation hole with your fingers, take a long deep breath and hold your breath (at least 3-4 seconds).

Side effects

Possible adverse reactions (very often (≥1 / 10), often (≥1 / 100 and <1/10), infrequently (≥1 / 1000 and <1/100), rarely (≥ 1/10 000 and <1 / 1000), very rare (<1/10 000, including isolated cases)):

• respiratory system: often - cough;
• cardiovascular system: infrequently - atrial fibrillation, tachycardia;
• digestive system: often - constipation, dry mouth;
• parasitic and infectious diseases: often - pharyngitis.

special instructions

Anoro Ellipta should not be used in bronchial asthma (due to the lack of a safety profile for this category of patients).

The drug is not intended for the relief of acute symptoms (as an emergency aid in acute episodes of bronchospasm). Short-acting bronchodilators should be used to relieve acute symptoms. An increase in the frequency of their use may indicate a deterioration in control over the disease (consultation with a specialist is required).

The use of Anoro Ellipt can lead to the development of life-threatening paradoxical bronchospasm. In these cases, therapy is canceled.

Patients under the age of 40 years, before the appointment of Anoro Ellipt, need to confirm the diagnosis spirometrically.

Drug interactions

With the combined use of Anoro Ellipt with some drugs / substances, the following effects may develop:

• beta-blockers: weakening / antagonism of the action of Anoro Ellipt (without good reason, combined use is not recommended);
• strong inhibitors of the isoenzyme CYP3A4 (for example, ketoconazole): an increase in systemic exposure of vilanterol and the likelihood of adverse reactions (the combination requires caution).

Analogs

There is no information about analogues of the Anoro Ellipta drug.

Terms and conditions of storage

Keep out of reach of children at temperatures up to 25 ° C.

Shelf life is 2 years.

After opening the aluminum container, the drug can be used for 6 weeks.

Terms of dispensing from pharmacies

Dispensed by prescription.

Anoro Ellipta: prices in online pharmacies

Drug name Price Pharmacy

Anoro Ellipta 22 mcg + 55 mcg / dose 30 doses powder for inhalation dosed 1 pc. 2043 RUB Buy

Anoro Ellipta powder for in. dosage. 22mcg + 55mcg / dose 30 doses (for inhaler with 2 strips) RUB 2168 Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!